Newsroom

July 29, 2019
VALEO PHARMA WARRANTS TO BEGIN TRADING ON CSE UNDER THE SYMBOL VPH.WT
July 25, 2019
VALEO PHARMA ANNOUNCES CLOSING OF $3.1 MILLION PROSPECTUS OFFERING OF UNITS AND DEBT CONVERSION OF $1.0 MILLION
July 15, 2019
VALEO PHARMA FILES FINAL SHORT FORM PROSPECTUS FOR ITS UNIT OFFERING
July 10, 2019
Valeo Pharma Announces the Canadian Launch of Onstryv (Safinamide Tablets) for the Treatment of Parkinson’s Disease
July 8, 2019
Valeo Pharma Enters into a Licensing Agreement for Canadian Rights to Heparin Biosimilar
July 3, 2019
VALEO PHARMA REPORTS ITS SECOND QUARTER 2019 FINANCIAL RESULTS
May 27, 2019
VALEO PHARMA ANNOUNCES PRICING OF $0.50 PER UNIT AND WARRANT TERMS FOR ITS PROSPECTUS OFFERING
May 1, 2019
Valeo Pharma Announces Short Form Prospectus Unit Offering and Refiling of Its Condensed Consolidated Interim Financial Statements and Related MD&A
March 27, 2019
Valeo Pharma Inc. Reports 2019 First Quarter Results
February 20, 2019
Valeo Pharma Announces Listing of its Shares on the Canadian Securities Exchange Under the Symbol VPH.
February 19, 2019
Valeo Pharma Completes Private Placement
January 15, 2019
Valeo Pharma and Zambon announce the approval of Onstryv® (safinamide tablets) for Canada
January 3, 2019
Valeo Pharma Announces Filing of Final Non-Offering Prospectus
April 11, 2017
Valeo Pharma and Zambon form partnership for Parkinson's Disease Treatment Xadago® (safinamide) in Canada
February 19, 2015
Valeo Pharma announces Distribution Agreement for Synacthen® Depot in Canada